Advertisement
Research Article

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

  • Birgit Engesæter mail,

    birgite@rr-research.no

    Affiliation: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway

    X
  • Olav Engebraaten,

    Affiliations: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway, Department of Oncology, Oslo University Hospital, Oslo, Norway, Institute for Clinical Research, Medical Faculty, University of Oslo, Oslo, Norway

    X
  • Vivi Ann Flørenes,

    Affiliation: Department of Pathology, Oslo University Hospital, Oslo, Norway

    X
  • Gunhild Mari Mælandsmo

    Affiliations: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway, Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway

    X
  • Published: September 20, 2012
  • DOI: 10.1371/journal.pone.0045492

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.